AIA
UTHR icon

Affinity Investment Advisors’s United Therapeutics UTHR Stock Holding History

Affinity Investment Advisors’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,650
Closed -$296K – 213
2022
Q1 		$296K Buy
1,650
+222
+16% +$42.3K 0.12% 168
2021
Q4 		$309K Buy
+1,428
New +$280K 0.12% 160

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Affinity Investment Advisors's UTHR Position: Q2 2022 in Review

Affinity Investment Advisors sold out of United Therapeutics (UTHR) in Q2 2022, closing a stake of 1,650 shares — an estimated $296K sold.

Affinity Investment Advisors first reported a position in UTHR in Q4 2021 and held it in 2 quarters. The position peaked at $309K in Q4 2021. 472 funds tracked by Wall St. Rank hold UTHR as of Q2 2022.

  • Affinity Investment Advisors reported no remaining United Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Affinity Investment Advisors sold 1,650 United Therapeutics shares in Q2 2022, an estimated $296K.
  • Affinity Investment Advisors first reported a position in United Therapeutics in Q4 2021 and held it in 2 quarters.
  • Affinity Investment Advisors's United Therapeutics position peaked at $309K in Q4 2021.
  • 472 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2022.

Based on Affinity Investment Advisors's 13F filing for Q2 2022, filed 27 Jul 2022.